1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Drugs In Development, 2022, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 5, 9 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Narcolepsy - Overview
- Narcolepsy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Narcolepsy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Narcolepsy - Companies Involved in Therapeutics Development
- Axsome Therapeutics Inc
- Bioprojet SCR
- Centessa Pharmaceuticals Plc
- ConSynance Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Gubra ApS
- Inexia Ltd
- Jazz Pharmaceuticals Plc
- KemPharm Inc
- Lennham Pharmaceuticals Inc
- NLS Pharmaceutics AG
- Ono Pharmaceutical Co Ltd
- Seelos Therapeutics, Inc.
- SK Biopharmaceuticals Co Ltd
- Sumitomo Pharma Co Ltd
- Sunovion Pharmaceuticals Inc
- Suven Life Sciences Ltd
- Synchronicity Pharma Inc
- Takeda Pharmaceutical Co Ltd
- Theranexus SA
- Vallon Pharmaceuticals Inc
- XWPharma Ltd
- Narcolepsy - Drug Profiles
- (flecainide acetate + modafinil) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ALKS-2680 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- danavorexton - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- dextroamphetamine IR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DSP-0187 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GUI-36 - Drug Profile
- Product Description
- Mechanism Of Action
- HBS-102 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KP-1077 - Drug Profile
- Product Description
- Mechanism Of Action
- mazindol ER - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NLS-2 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NLS-4 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ONO-2909 - Drug Profile
- Product Description
- Mechanism Of Action
- OPN-021 - Drug Profile
- Product Description
- Mechanism Of Action
- OX2 agonist - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OX2 agonist (Oral) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Oxybate - Drug Profile
- Product Description
- Mechanism Of Action
- Peptides to Agonize Orexin 2 Receptor for Narcolepsy and Unspecified Neurologic Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- pitolisant hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- reboxetine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RO-5256390 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- samelisant - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SLS-010 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Antagonize ADORA for Central Nervous System - Drug Profile
- Product Description
- Mechanism Of Action
- solriamfetol hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TAK-861 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TAK-994 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ulotaront - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- valiloxybate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- YNT-185 - Drug Profile
- Product Description
- Mechanism Of Action
- Narcolepsy - Dormant Projects
- Narcolepsy - Discontinued Products
- Narcolepsy - Product Development Milestones
- Featured News & Press Releases
- Jul 21, 2022: NLS pharmaceutics announces positive opinion from European Regulators to grant Orphan Drug Designation for Mazindol ER in idiopathic hypersomnia
- Jun 28, 2022: Axsome Therapeutics hosts Sunosi investor update virtual event today with Key Opinion Leaders
- Jun 28, 2022: Axsome Therapeutics to host Sunosi investor update virtual event
- Jun 08, 2022: Harmony Biosciences presents post-hoc analysis of WAKIX (pitolisant) pivotal data in adults with high burden of narcolepsy symptoms
- Jun 02, 2022: NLS Pharmaceutics announces over enrollment in its phase 2a clinical trial evaluating Quilience(R) for the treatment of narcolepsy
- May 12, 2022: Vallon Pharmaceuticals reports additional pharmacokinetic and pharmacodynamic data from SEAL study of ADAIR
- May 04, 2022: NLS Pharmaceutics achieves 90% enrollment milestone in Quilience phase 2a clinical trial for patients with narcolepsy
- Mar 28, 2022: NLS Pharmaceutics announces Early Access Program (EAP) allowing patients with idiopathic hypersomnia to receive treatment with Mazindol ER
- Mar 16, 2022: NLS Pharmaceutics announces positive interim top-line data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
- Feb 23, 2022: KemPharm completes KP1077 Pre-IND meeting process with FDA
- Feb 07, 2022: NLS Pharmaceutics to present interim top-line data for Quilience (Mazindol ER) in patients with narcolepsy at the World Sleep Congress in March 2022
- Feb 07, 2022: Aculys Pharma begins Japan PI for narcolepsy drug candidate
- Dec 13, 2021: Harmony Biosciences publishes pitolisant efficacy data in CNS Drugs
- Nov 18, 2021: National Institute for Health and Care Excellence (NICE) issues positive guidance for Jazz Pharmaceuticals' Sunosi (solriamfetol) for the treatment of adults with excessive daytime sleepiness (EDS) caused by narcolepsy
- Oct 06, 2021: Takeda to stop Phase II trials of TAK-994 due to safety signal
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Narcolepsy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Narcolepsy - Pipeline by Axsome Therapeutics Inc, 2022
- Narcolepsy - Pipeline by Bioprojet SCR, 2022
- Narcolepsy - Pipeline by Centessa Pharmaceuticals Plc, 2022
- Narcolepsy - Pipeline by ConSynance Therapeutics Inc, 2022
- Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Narcolepsy - Pipeline by Gubra ApS, 2022
- Narcolepsy - Pipeline by Inexia Ltd, 2022
- Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, 2022
- Narcolepsy - Pipeline by KemPharm Inc, 2022
- Narcolepsy - Pipeline by Lennham Pharmaceuticals Inc, 2022
- Narcolepsy - Pipeline by NLS Pharmaceutics AG, 2022
- Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Narcolepsy - Pipeline by Seelos Therapeutics, Inc., 2022
- Narcolepsy - Pipeline by SK Biopharmaceuticals Co Ltd, 2022
- Narcolepsy - Pipeline by Sumitomo Pharma Co Ltd, 2022
- Narcolepsy - Pipeline by Sunovion Pharmaceuticals Inc, 2022
- Narcolepsy - Pipeline by Suven Life Sciences Ltd, 2022
- Narcolepsy - Pipeline by Synchronicity Pharma Inc, 2022
- Narcolepsy - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Narcolepsy - Pipeline by Theranexus SA, 2022
- Narcolepsy - Pipeline by Vallon Pharmaceuticals Inc, 2022
- Narcolepsy - Pipeline by XWPharma Ltd, 2022
- Narcolepsy - Dormant Projects, 2022
- Narcolepsy - Dormant Projects, 2022 (Contd..1)
- Narcolepsy - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Narcolepsy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Axsome Therapeutics Inc
- Bioprojet SCR
- Centessa Pharmaceuticals Plc
- ConSynance Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Gubra ApS
- Inexia Ltd
- Jazz Pharmaceuticals Plc
- KemPharm Inc
- Lennham Pharmaceuticals Inc
- NLS Pharmaceutics AG
- Ono Pharmaceutical Co Ltd
- Seelos Therapeutics, Inc.
- SK Biopharmaceuticals Co Ltd
- Sumitomo Pharma Co Ltd
- Sunovion Pharmaceuticals Inc
- Suven Life Sciences Ltd
- Synchronicity Pharma Inc
- Takeda Pharmaceutical Co Ltd
- Theranexus SA
- Vallon Pharmaceuticals Inc
- XWPharma Ltd
